ASH 2025 | Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses patient-reported outcomes from the ASC4FIRST study (NCT04971226) of asciminib versus investigator-selected tyrosine kinase inhibitors in newly diagnosed chronic myeloid leukemia (CML). Dr Cortes reports significant improvements in quality of life for patients receiving asciminib. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In this abstract, we are presenting data from the ASC4FIRST study, which was this randomized study in first-line therapy of asciminib versus all the available tyrosine kinase inhibitors approved for front-line therapy. These main results have been presented, have been published. It showed the benefit in terms of efficacy of asciminib and also a similar safety profile, probably even a little bit better than the comparators...
In this abstract, we are presenting data from the ASC4FIRST study, which was this randomized study in first-line therapy of asciminib versus all the available tyrosine kinase inhibitors approved for front-line therapy. These main results have been presented, have been published. It showed the benefit in terms of efficacy of asciminib and also a similar safety profile, probably even a little bit better than the comparators. But one of the important questions is the quality of life for the patients, because that’s one of the problems that patients face, especially since they’re going to be receiving treatment for a long period of time. So in that study, in the ASC4FIRST, we followed the patient-reported outcomes with a variety of instruments that measure different aspects of quality of life. Some of them are more symptom-oriented, some of them are more function-oriented, and others are more of an overall quality of life measure. And we assess them at baseline, and then we assess them at 48 weeks and at 96 weeks. And what we saw in these results is that there seems to be, this analysis mostly looks at the changes from baseline in the quality of life. And what it shows is that there is an improvement over baseline, and that improvement is more significant for the patients that received asciminib versus the patients that received any of the other tyrosine kinase inhibitors. The overall quality of life, which is probably the most informative, is significantly better for the patients on asciminib. And for the individual symptoms and the others, most of them also benefit asciminib. Others are more similar. But overall, it suggests that there is a benefit in quality of life for asciminib compared to the other tyrosine kinase inhibitors. So this is important because again patients are interested of course in getting a good response but they’re also interested in maintaining their quality of life and this gives us some information in that regard.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
